Dr Ira Longini | Professor & Co-director, Center for Statistics and Quantitative Infectious Diseases (CSQUID) Emerging Pathogens Institute
University of Florida

Dr Ira Longini, Professor & Co-director, Center for Statistics and Quantitative Infectious Diseases (CSQUID) Emerging Pathogens Institute, University of Florida

Ira Longini is currently a Professor in the Department of Biostatistics, College of Public Health and Health Professions, with joint affiliation in the Department of Statistics, Center for Quantitative Infectious Diseases, and the Emerging Pathogens Institute, at the University of Florida, and the Department of Statistics at the University of Washington. His primary research topics are statistical methods and mathematical methods for assessing transmissibility and intervention effectiveness for infectious diseases.


DC Pre-congress WS day April 2 @ 2:00

Workshop D:The role of vaccines in preventing outbreaks, through natural causes or biothreats: The WHO blueprint

It only takes natural outbreaks like the Ebola and Zika viruses to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.

Public-private partnerships for pandemic influenza and emerging infectious disease vaccine preparedness and response

The WHO blueprint: Nipah, MERS, LASSA, Zika, Chik

Modelling for dangerous pathogens and estimating vaccine efficacy

DC Co-conference Day 2 April 4 @ 3:10

How can vaccines and vector control be integrated and used synergistically in a control program

·         Clinical development challenges associated with the design and conduct of emerging epidemic trials

·         Current status of Zika Vaccine candidates in Clinical Development

·         Geographical Considerations: Epidemiology v Trial Locations

·         Considerations for Zika Vaccine Clinical Development Strategy

back to speakers